The Chemours Company (CC) Financials
Key financial figures for The Chemours Company (Q3 2026).
Chemours Q3 2026 net sales rose 3% to $1.540B and Adjusted EBITDA rose to $200M from $189M as Titanium Technologies pricing offset a 30% Adjusted EBITDA drop in Thermal & Specialized Solutions; full-year Adjusted EBITDA guidance narrowed to $775-$800M from $775-$825M. Net sales were $1,540M versus $1,495M a year earlier (+3%): price added 5%, volume subtracted 2% and currency was a slight headwind. The FMP calendar consensus for revenue was $1.532B (single aggregator, net sales basis), so sales landed slightly above it. GAAP gross profit was $231M versus $233M. GAAP net income attributable to Chemours was $196M, or $1.29 per diluted share, versus $46M, or $0.31. The release says the quarter includes $150M received under the PFAS insurance proceeds MOU, presented as a reduction to SG&A. On the outlook: Q4 2026: consolidated net sales down 5% to 10% sequentially, Adjusted EBITDA $160M-$185M, corporate expenses $40M-$45M, capex $75M-$85M, positive Free Cash Flows; TSS Adjusted EBITDA $105M-$115M, TT $60M-$65M, APM $40M-$45M. Full year 2026: net sales growth of about 2%, Adjusted EBITDA $775M-$800M (prior outlook $775M-$825M), capex $220M-$230M, Free Cash Flow Conversion above 15%, and net leverage below 4.2x (prior outlook around 3.8x). Figures are for Q3 2026, as The Chemours Company reported them.
- Revenue
- $1.5B
- Net Income
- $196M
- EPS
- $1.29
- Total Assets
- $7.3B
- Operating Cash Flow
- $149M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $1.5B | $196M | $1.29 | $98M | |
| Q2 FY2026 | $1.6B | -$274M | -$1.81 | $21M | |
| Q1 FY2026 | $1.4B | -$29M | -$0.19 | -$93M | |
| Q4 FY2025 | $1.3B | -$61M | -$0.39 | $92M | |
| Q3 FY2025 | $1.5B | $60M | $0.40 | $105M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $5.8B | -$386M | -$2.57 | $51M | |
| FY2024 | $5.8B | $86M | $0.57 | -$993M | |
| FY2023 | $6.1B | -$238M | -$1.70 | $186M |
Frequently asked questions
What was The Chemours Company's revenue last quarter?
The Chemours Company reported revenue of $1.54 billion for Q3 FY2026, up 3.0% from the same period a year earlier.
Is The Chemours Company profitable?
Yes. The Chemours Company reported net income of $196.0 million for Q3 FY2026, a net margin of 12.73% on revenue.
How much free cash flow did The Chemours Company generate?
The Chemours Company generated free cash flow of $98.0 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for The Chemours Company on SentiSense, with up to forty quarters and twenty fiscal years of history.